WILSON - 修訂歷史

Vickyho在2007年11月24日 (六) 05:41

2007-11-24T05:41:25Z

←上一修訂		在2007年11月24日 (六) 05:41所做的修訂版本
第13行：		第13行：
	是世代遺傳的隱性遺傳		是世代遺傳的隱性遺傳

-	~~'''~~'	+	'

-	~~'''~~'	+	'

	''病理生理學''		''病理生理學''

-	~~'''~~'	+	'

-	~~'''~~'	+	'

	''標誌和症狀''		''標誌和症狀''
第27行：		第27行：
	肝臟病		肝臟病

-	~~'''~~'	+	'

-	~~'''~~'	+	'

	''診斷''		''診斷''
第35行：		第35行：
	24小時U/A >100.g/24		24小時U/A >100.g/24

-	~~'''~~'	+	'

-	~~'''~~'	+	'

	''治療''		''治療''
第43行：		第43行：
	肝移植		肝移植

-	~~'''~~'	+	'

-	~~'''~~'	+	'

	''結果''		''結果''
第51行：		第51行：
	恢復的慢		恢復的慢

-	~~無法恢復~~	+
		+
		+	參考資料:[http://tw.knowledge.yahoo.com/question/?qid=1105060802088]
		+
		+	參考資料:[http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/gastro/wilsons/wilsons.htm]
		+
		+
		+
		+

	<br>		<br>

Vickyho在2007年11月24日 (六) 05:36

2007-11-24T05:36:22Z

←上一修訂		在2007年11月24日 (六) 05:36所做的修訂版本
第1行：		第1行：
	wilson's disease		wilson's disease

-	定義	+	''定義''

		+	<br>因無法代謝銅

-	~~因無法代謝~~	+	<br>使的銅在肝臟與腦子聚積

		+	<br>排泄混亂的代謝性疾病

-	銅	+	''流行''

		+	是世代遺傳的隱性遺傳

-	~~使的銅~~	+	''''

		+	''''

-	~~在肝臟與腦子聚積~~	+	''病理生理學''

		+	''''

-	~~排泄混亂的~~	+	''''

		+	''標誌和症狀''

-	~~代謝性疾病~~	+	肝臟病

-	流行	+	''''

-	~~是世代遺傳的隱性遺傳~~	+	''''

-	~~病理生理學~~	+	''診斷''

-	~~標誌和症狀~~	+	24小時U/A >100.g/24

-	~~肝臟病~~	+	''''

-	診斷	+	''''

-	~~24小時U/A >100.g/24~~	+	''治療''
-		+
-	治療	+

	肝移植		肝移植

-	結果	+	''''
		+
		+	''''
		+
		+	''結果''

	恢復的慢		恢復的慢
第45行：		第53行：
	無法恢復		無法恢復

-		+	<br>

Vickyho在2007年11月24日 (六) 05:32

2007-11-24T05:32:41Z

←上一修訂		在2007年11月24日 (六) 05:32所做的修訂版本
第1行：		第1行：
	wilson's disease		wilson's disease
		+
		+	定義
		+
		+
		+	因無法代謝
		+
		+
		+	銅
		+
		+
		+	使的銅
		+
		+
		+	在肝臟與腦子聚積
		+
		+
		+	排泄混亂的
		+

	代謝性疾病		代謝性疾病

-	~~無法代謝銅~~	+	流行
		+
		+	是世代遺傳的隱性遺傳
		+
		+	病理生理學
		+
		+	標誌和症狀
		+
		+	肝臟病
		+
		+	診斷
		+
		+	24小時U/A >100.g/24
		+
		+	治療
		+
		+	肝移植
		+
		+	結果
		+
		+	恢復的慢
		+
		+	無法恢復
		+
		+
		+
		+

Vickyho: 正在將頁面替換為 'wilson's disease 代謝性疾病無法代謝銅'

2007-11-21T04:00:25Z

正在將頁面替換為 'wilson's disease 代謝性疾病無法代謝銅'

←上一修訂		在2007年11月21日 (三) 04:00所做的修訂版本
第1行：		第1行：
	wilson's disease		wilson's disease

-	DEFINITION <br>Wilson disease (WD) is a genetic disorder in which there is excessive accumulation of copper in the liver and brain because of an inherited defect in the biliary excretion of copper.2 A comprehensive practice guideline has recently been published by the American Association for the Study of Liver Diseases representing the state of the art management of Wilson Disease. Recommendations on this review are consistent with that guideline.1<br><br>PREVALENCE <br>WD is transmitted from generation to generation by autosomal recessive inheritance. Only homozygotes for this disorder who inherit disease-specific mutations2,3 of both alleles of the Wilson's disease gene may go on to manifest clinical evidence of the condition. Such individuals have been described in many different races and number about 1 in 30,000 of the worldwide population. As will be described later, particular mutations are found more frequently in specific populations or ethnic groups with varying phenotypic expression in certain of these mutations. However, it is known that heterozygotes with a mutation of a single allele do not develop disease although they may show varying degrees of abnormality in serum copper markers.<br><br>PATHOPHYSIOLOGY <br>Copper is an essential cofactor for many enzymes and proteins and plays a role in the mobilization of tissue iron stores. Copper in the diet is absorbed relatively efficiently by the small intestine, is bound relatively loosely by circulating plasma proteins, and is delivered to the liver from the portal circulation. The transport of copper from the hepatocytes to bile is critical in overall copper homeostasis since biliary excretion undergoes minimal enterohepatic recirculation. The protein ATP7B is important in the vesicular pathway of hepatic copper transport into bile.3 The WD gene mutation leads to absence or diminished function of ATP7B, resulting in a decrease in biliary copper excretion4,5 and ultimately the hepatic accumulation of copper. Along with this failure of biliary excretion, there is also reduced incorporation of copper into ceruloplasmin, which is a serum glycoprotein that contains six copper atoms per molecule and is synthesized predominantly in the liver. The process of copper incorporation into apoceruloplasmin is also dependent on ATP7B, and this process is absent or diminished in most patients with WD, leading to a reduced circulating level of serum ceruloplasmin in most patients.6	+	代謝性疾病

-		+	無法代謝銅
-		+
-	When copper accumulates beyond the normal safe storage capacity of the liver, hepatocellular injury results. Furthermore, when the storage capacity of the liver for copper is exceeded or when additional cellular copper is released because of hepatocellular damage, levels of non-ceruloplasmin-bound copper in the circulation are elevated and copper accumulates in multiple extrahepatic sites, in particular the brain. As copper "spills" over to other organs from the liver, pathologic manifestations become evident in the brain, kidneys, eyes, and joints.	+
-		+
-	The pathologic evidence for copper accumulation in the liver evolves from early infancy to adult life. The earliest pathologic changes may consist of steatosis and distinctive mitochondrial changes. With progression and without treatment, the liver may show signs indistinguishable from chronic hepatitis and ultimately develops cirrhosis. In some instances, fulminant hepatic failure with parenchymal necrosis and collapse of tissue may be evident. In the brain, the predominant neuropathologic changes of advanced untreated WD are concentrated in the lenticular nuclei, which have the highest copper levels and with increasing copper accumulation undergo various of forms of degeneration. Likewise, abnormalities in the renal tubules and glomeruli, periarticular and articular tissues, and the eyes may all become sites of evidence for copper damage.<br><br>SIGNS AND SYMPTOMS <br>Signs and symptoms of liver disease, neurologic and psychiatric disease are the most common clinical presentations of symptomatic WD (Table 2). In contrast, individuals found by family screening are frequently asymptomatic.7 Failure to diagnose and treat WD results in the development of hepatic insufficiency, ultimately hepatic failure and, in some patients, neuropsychiatric disease.	+
-		+
-	The clinical spectrum of liver disease in WD patients varies widely. Younger patients may be found either by family screening or by the presence of isolated abnormalities on liver tests. Overt disease may be delayed in some patients, and they may present with features of chronic liver disease indistinguishable from other forms of chronic active hepatitis or end-stage liver disease. In the latter circumstance of established cirrhosis, features of portal hypertension such as ascites, edema, or hypersplenism and hepatic encephalopathy may be observed. If untreated, these individuals will progress ultimately to hepatic insufficiency, liver failure, and death. There are, unfortunately, some individuals whose disease may be obscured until their adolescent years, when they may present with fulminant hepatitis and associated hemolytic anemia. These are circumstances that are frequently fatal without timely, life-saving OLT.	+
-		+
-	There are other patients with WD whose first presenting symptoms are either neurologic or psychiatric, and they are frequently patients in the third decade of life or even older. Most of these patients with central nervous system disease have occult significant liver disease at the time of presentation. The neurologic disease manifests predominantly as motor abnormalities with parkinsonian features of dystonia, hypertonia, and rigidity with tremors and dysarthria. These may cause disabling symptoms that include muscle spasms, dysarthria, dystonia, and dysphagia.	+
-		+
-	~~In rarer circumstances, WD may present with abnormalities of other organ systems, namely, renal tubular abnormalities, arthropathy, and cardiomyopathy with dysrhythmias.~~	+
-		+
-	Ophthalmologic findings include Kayser-Fleischer rings and sunflower cataracts. The Kayser-Fleischer ring is most marked at the upper and lower poles of the limbus, the junction between cornea and sclera, and are due to granular deposition of elemental copper on the inner surface of the cornea in Descemet's membranes. The rings have a golden brown or greenish appearance on slit-lamp examination. By the time the neurologic changes occur, usually in the third decade of life, the Kayser-Fleischer rings are almost invariably present although there are exceptions to this rule.<br><br>DIAGNOSIS <br>WD should be considered and excluded in any individual between childhood and age 40 years who has unexplained hepatic, neurologic, or psychiatric disease (Table 3). In particular, it should be considered in children or young adults with atypical extrapyramidal or cerebellar motor dysfunction, neuropsychiatric disease, elevated aminotransferases, or other features of acute or subacute liver disease and with unexplained non-immune-mediated hemolysis. In these circumstances, WD must be considered whether or not there is a family history of liver or neurologic disease. In most cases, the diagnosis can be confirmed on the basis of clinical and biochemical evaluation without the need for liver biopsy.	+
-		+
-	~~As a practical algorithm, there are three levels of tests that are used to confirm the diagnosis of Wilson's disease (Table 3).~~	+
-		+
-	Level 1 tests consist of serum ceruloplasmin concentration, total serum copper concentration and, by derivation, the circulating non-ceruloplasmin-bound copper concentration, 24-hour urine copper excretion together with slit-lamp examination of the eyes for Kayser-Fleischer rings.<br>The serum ceruloplasmin concentration is routinely available in all clinical laboratories and has a normal range of 20 to 50 mg/dL. Approximately 95% of homozygous WD patients have values < 20 mg/dL. It should be noted, however, that 5% of all homozygotes, whether symptomatic or not, and 15% to 50% of WD patients with liver disease, may maintain normal levels of ceruloplasmin. Spuriously normal levels of ceruloplasmin may occur as a result of acute-phase responses based on active inflammation. Conversely, low serum ceruloplasmin concentrations may occur in a variety of hypoproteinemic states and in up to 20% of asymptomatic WD heterozygotes. A very rare cause of extremely low ceruloplasmin levels may be hereditary aceruloplasminemia.	+
-		+
-	The total serum copper concentration is made up of ceruloplasmin-bound copper and "free" copper bound more loosely to albumin or smaller circulating peptides. The ceruloplasmin and therefore the ceruloplasmin copper are typically low in WD and may explain an overall reduction in total serum copper. However, when the free (eg, non-ceruloplasmin bound) copper is calculated by subtracting the ceruloplasmin copper from the total serum copper, this is usually found to be elevated, typically to > 25 µg/dL in WD. To calculate the free copper, the ceruloplasmin in mg/dL is multiplied by 3 and this number is then subtracted from the total serum copper in µg/dL.	+
-		+
-	Slit-lamp evaluation of the cornea for Kayser-Fleischer rings should be performed by an experienced ophthalmologist. Kayser-Fleischer rings are present in virtually every patient with neurologic disease, but may be absent in younger patients with hepatic manifestations only.	+
-		+
-	The measurement of 24-hour urinary copper excretion of the usually exceeds 100 µg/24 hr in WD and reflects the increased plasma non-ceruloplasmin bound copper. Spuriously elevated increases in urinary copper may occur in the face of fulminant liver failure and in patients with nephrotic levels of proteinuria. It should be emphasized that the collection of 24-hour specimens must be made into metal-free containers.	+
-		+
-	In the absence of Kayser-Fleischer rings level 2 tests are important for diagnostic confirmation of WD. Liver biopsy for hepatic copper concentrations is an invaluable diagnostic tool. Most homozygotes for WD have levels > 250 µg/g dry weight with normal values rarely exceeding 50 µg/g. Intermediate values may be seen in heterozygotes. A number of hepatic conditions manifesting extreme cholestasis may have elevated hepatic copper concentrations but can usually be diagnosed by other clinical, serologic, or histologic criteria. Liver biopsies may be evaluated for copper concentration after being dried overnight at 56°C in a vacuum oven with part of the biopsy specimen separated and fixed in formalin prior to histopathologic evaluation. The evaluation should include immunohistochemical staining for copper.	+
-		+
-	Level 3 tests include incorporation of radiocopper into ceruloplasmin and molecular genetic studies to provide evidence for mutations in the ATP7B gene. In practice, the incorporation of isotopes of copper into ceruloplasmin is impractical in most centers. Such tests have been used to validate the diagnosis of WD in the minority of patients with normal ceruloplasmin levels, or where there was previously a contraindication to liver biopsy. The availability of the transjugular route of liver biopsy has made such tests unnecessary in most circumstances.	+
-		+
-	Currently, molecular genetic studies are confined to haplotype analysis of family members of an affected individual. Such tests involve evaluation of DNA polymorphisms in the nucleotide regions surrounding the ATP7B gene. There have been multiple disease-specific mutations of the WD gene described in probands with the disorder. Even the most common of these mutations account for only 15% to 30% of most WD populations. Newer technologies that utilize molecular genetic testing in newly discovered patients with clinical manifestations of the disease might pinpoint disease-specific mutations in contradistinction to polymorphisms of the gene. <br><br>TREATMENT <br>Depending on the mode of presentation of WD, treatment options consist of either orally administered pharmacologic agents (Table 4) or OLT. Liver transplantation should not be regarded as a treatment of last resort, but it may be the only means of timely intervention in patients presenting with acute or subacute liver failure or decompensating end-stage liver disease. Ideally, patients should be diagnosed early enough for medical therapy to attenuate or abolish symptoms and prevent progression of the disease. <br>It is generally agreed that patients with symptoms or signs of hepatic insufficiency or chronic active hepatitis with or without neurologic manifestations should be offered chelation therapy with penicillamine or trientine. These drugs are administered orally and remove copper from potentially toxic sites. In contrast, zinc salts serve to block the intestinal absorption of dietary copper by stimulating the synthesis of a variety of endogenous copper chelators such as metallothioneins. Penicillamine was the first copper chelator to be developed and unfortunately has been incriminated in a variety of toxic side effects that lead to discontinuation of the drug in 10% to 15% of patients1,8,9 Trientine was developed more recently and is considered preferable by many experts as first-line therapy in patients with hepatic and/or neurologic disease. Zinc salts may be considered as initial therapy for asymptomatic patients or for those intolerant of penicillamine or trientine.8 With any of these treatments, patients should be evaluated for clinical and biochemical improvement and normalization of markers of copper metabolism, in particular the level of free serum copper and urinary copper output. With stabilization of these clinical and biochemical parameters, patients may be switched to maintenance therapy. This may consist of reduction in the dose of penicillamine or trientine or, in some cases, switching from these chelating agents to zinc salts (Table 4).	+
-		+
-	Dietary intake of foods rich in copper should be avoided, particularly during the initial phase of treatment. Organ meats, nuts, chocolate, and shellfish should be avoided. These restrictions may be partially lifted during the maintenance phase of treatment.	+
-		+
-	For WD patients who become pregnant, the doses of penicillamine or trientine should be reduced during the second trimester and the first 2 months of the third trimester to 500 mg/day maximum, and to 250 mg/day for the month before delivery and for up to 1 month postpartum.8,10 A similar approach to reduction in therapy with chelating agents is applied to patients undergoing surgery, to allow wound healing to be completed.	+
-		+
-	The key to long-term success of pharmacologic treatment for WD is the patient's adherence to treatment. Evaluation of response is based upon improvement in the signs of liver or neurologic disease and improvement in biochemical markers of liver function. Further assessment is based on periodic monitoring of urinary copper output, slit-lamp examinations and, most important, by reduction in the level of non-ceruloplasmin-bound copper in the serum. With adequacy of treatment, this should fall to 10 µg/dL or less. Inadequate treatment or failure of compliance is usually associated with a level above 25 µg/dL. In the context of chelation therapy, urinary copper excretion initially exceeds 1,000 µg/day, and subsequently on maintenance treatment should be between 250 and 500 µg/day. Values less than this usually suggest nonadherence to treatment. In contrast, on zinc therapy, urinary copper excretion usually falls to < 150 µg/day.	+
-		+
-	OLT is indicated in the extreme circumstances mentioned above, when there is evidence of impending liver failure.11 Transplant recipients develop the normal donor phenotype with regard to markers of copper metabolism and do not require additional pharmacologic therapy for WD, except possibly in the circumstances of residual neurologic symptoms and signs.<br><br>OUTCOMES <br>Even with established cirrhosis or chronic active hepatitis, the prognosis is excellent for patients who adhere fully to pharmacologic therapy. Neurologic or psychiatric symptoms may be slow to recover and may not be completely reversible. However, features of both neurologic disease and hepatic insufficiency usually stabilize on treatment, and only a watch-and-wait approach can be recommended. In cases of liver decompensation, following OLT 1-year survival is comparable to that for other causes of liver failure.11 Although neurologic symptoms may improve post-OLT, the extent of neurologic involvement itself in the absence of liver failure is not an indication for OLT.	+
-		+
-	~~<br>~~	+
-		+
-	~~資料來源:[http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/gastro/wilsons/wilsons.htm]~~	+

Vickyho: 新頁面: wilson's disease DEFINITION
Wilson disease (WD) is a genetic disorder in which there is excessive accumulation of copper in the liver and brain because of an inherited defect in the ...

2007-11-21T03:47:48Z

新頁面: wilson's disease DEFINITION Wilson disease (WD) is a genetic disorder in which there is excessive accumulation of copper in the liver and brain because of an inherited defect in the ...

新頁面

wilson's disease

DEFINITION Wilson disease (WD) is a genetic disorder in which there is excessive accumulation of copper in the liver and brain because of an inherited defect in the biliary excretion of copper.2 A comprehensive practice guideline has recently been published by the American Association for the Study of Liver Diseases representing the state of the art management of Wilson Disease. Recommendations on this review are consistent with that guideline.1 PREVALENCE WD is transmitted from generation to generation by autosomal recessive inheritance. Only homozygotes for this disorder who inherit disease-specific mutations2,3 of both alleles of the Wilson's disease gene may go on to manifest clinical evidence of the condition. Such individuals have been described in many different races and number about 1 in 30,000 of the worldwide population. As will be described later, particular mutations are found more frequently in specific populations or ethnic groups with varying phenotypic expression in certain of these mutations. However, it is known that heterozygotes with a mutation of a single allele do not develop disease although they may show varying degrees of abnormality in serum copper markers. PATHOPHYSIOLOGY Copper is an essential cofactor for many enzymes and proteins and plays a role in the mobilization of tissue iron stores. Copper in the diet is absorbed relatively efficiently by the small intestine, is bound relatively loosely by circulating plasma proteins, and is delivered to the liver from the portal circulation. The transport of copper from the hepatocytes to bile is critical in overall copper homeostasis since biliary excretion undergoes minimal enterohepatic recirculation. The protein ATP7B is important in the vesicular pathway of hepatic copper transport into bile.3 The WD gene mutation leads to absence or diminished function of ATP7B, resulting in a decrease in biliary copper excretion4,5 and ultimately the hepatic accumulation of copper. Along with this failure of biliary excretion, there is also reduced incorporation of copper into ceruloplasmin, which is a serum glycoprotein that contains six copper atoms per molecule and is synthesized predominantly in the liver. The process of copper incorporation into apoceruloplasmin is also dependent on ATP7B, and this process is absent or diminished in most patients with WD, leading to a reduced circulating level of serum ceruloplasmin in most patients.6

When copper accumulates beyond the normal safe storage capacity of the liver, hepatocellular injury results. Furthermore, when the storage capacity of the liver for copper is exceeded or when additional cellular copper is released because of hepatocellular damage, levels of non-ceruloplasmin-bound copper in the circulation are elevated and copper accumulates in multiple extrahepatic sites, in particular the brain. As copper "spills" over to other organs from the liver, pathologic manifestations become evident in the brain, kidneys, eyes, and joints.

The pathologic evidence for copper accumulation in the liver evolves from early infancy to adult life. The earliest pathologic changes may consist of steatosis and distinctive mitochondrial changes. With progression and without treatment, the liver may show signs indistinguishable from chronic hepatitis and ultimately develops cirrhosis. In some instances, fulminant hepatic failure with parenchymal necrosis and collapse of tissue may be evident. In the brain, the predominant neuropathologic changes of advanced untreated WD are concentrated in the lenticular nuclei, which have the highest copper levels and with increasing copper accumulation undergo various of forms of degeneration. Likewise, abnormalities in the renal tubules and glomeruli, periarticular and articular tissues, and the eyes may all become sites of evidence for copper damage. SIGNS AND SYMPTOMS Signs and symptoms of liver disease, neurologic and psychiatric disease are the most common clinical presentations of symptomatic WD (Table 2). In contrast, individuals found by family screening are frequently asymptomatic.7 Failure to diagnose and treat WD results in the development of hepatic insufficiency, ultimately hepatic failure and, in some patients, neuropsychiatric disease.

The clinical spectrum of liver disease in WD patients varies widely. Younger patients may be found either by family screening or by the presence of isolated abnormalities on liver tests. Overt disease may be delayed in some patients, and they may present with features of chronic liver disease indistinguishable from other forms of chronic active hepatitis or end-stage liver disease. In the latter circumstance of established cirrhosis, features of portal hypertension such as ascites, edema, or hypersplenism and hepatic encephalopathy may be observed. If untreated, these individuals will progress ultimately to hepatic insufficiency, liver failure, and death. There are, unfortunately, some individuals whose disease may be obscured until their adolescent years, when they may present with fulminant hepatitis and associated hemolytic anemia. These are circumstances that are frequently fatal without timely, life-saving OLT.

There are other patients with WD whose first presenting symptoms are either neurologic or psychiatric, and they are frequently patients in the third decade of life or even older. Most of these patients with central nervous system disease have occult significant liver disease at the time of presentation. The neurologic disease manifests predominantly as motor abnormalities with parkinsonian features of dystonia, hypertonia, and rigidity with tremors and dysarthria. These may cause disabling symptoms that include muscle spasms, dysarthria, dystonia, and dysphagia.

In rarer circumstances, WD may present with abnormalities of other organ systems, namely, renal tubular abnormalities, arthropathy, and cardiomyopathy with dysrhythmias.

Ophthalmologic findings include Kayser-Fleischer rings and sunflower cataracts. The Kayser-Fleischer ring is most marked at the upper and lower poles of the limbus, the junction between cornea and sclera, and are due to granular deposition of elemental copper on the inner surface of the cornea in Descemet's membranes. The rings have a golden brown or greenish appearance on slit-lamp examination. By the time the neurologic changes occur, usually in the third decade of life, the Kayser-Fleischer rings are almost invariably present although there are exceptions to this rule. DIAGNOSIS WD should be considered and excluded in any individual between childhood and age 40 years who has unexplained hepatic, neurologic, or psychiatric disease (Table 3). In particular, it should be considered in children or young adults with atypical extrapyramidal or cerebellar motor dysfunction, neuropsychiatric disease, elevated aminotransferases, or other features of acute or subacute liver disease and with unexplained non-immune-mediated hemolysis. In these circumstances, WD must be considered whether or not there is a family history of liver or neurologic disease. In most cases, the diagnosis can be confirmed on the basis of clinical and biochemical evaluation without the need for liver biopsy.

As a practical algorithm, there are three levels of tests that are used to confirm the diagnosis of Wilson's disease (Table 3).

Level 1 tests consist of serum ceruloplasmin concentration, total serum copper concentration and, by derivation, the circulating non-ceruloplasmin-bound copper concentration, 24-hour urine copper excretion together with slit-lamp examination of the eyes for Kayser-Fleischer rings. The serum ceruloplasmin concentration is routinely available in all clinical laboratories and has a normal range of 20 to 50 mg/dL. Approximately 95% of homozygous WD patients have values < 20 mg/dL. It should be noted, however, that 5% of all homozygotes, whether symptomatic or not, and 15% to 50% of WD patients with liver disease, may maintain normal levels of ceruloplasmin. Spuriously normal levels of ceruloplasmin may occur as a result of acute-phase responses based on active inflammation. Conversely, low serum ceruloplasmin concentrations may occur in a variety of hypoproteinemic states and in up to 20% of asymptomatic WD heterozygotes. A very rare cause of extremely low ceruloplasmin levels may be hereditary aceruloplasminemia.

The total serum copper concentration is made up of ceruloplasmin-bound copper and "free" copper bound more loosely to albumin or smaller circulating peptides. The ceruloplasmin and therefore the ceruloplasmin copper are typically low in WD and may explain an overall reduction in total serum copper. However, when the free (eg, non-ceruloplasmin bound) copper is calculated by subtracting the ceruloplasmin copper from the total serum copper, this is usually found to be elevated, typically to > 25 µg/dL in WD. To calculate the free copper, the ceruloplasmin in mg/dL is multiplied by 3 and this number is then subtracted from the total serum copper in µg/dL.

Slit-lamp evaluation of the cornea for Kayser-Fleischer rings should be performed by an experienced ophthalmologist. Kayser-Fleischer rings are present in virtually every patient with neurologic disease, but may be absent in younger patients with hepatic manifestations only.

The measurement of 24-hour urinary copper excretion of the usually exceeds 100 µg/24 hr in WD and reflects the increased plasma non-ceruloplasmin bound copper. Spuriously elevated increases in urinary copper may occur in the face of fulminant liver failure and in patients with nephrotic levels of proteinuria. It should be emphasized that the collection of 24-hour specimens must be made into metal-free containers.

In the absence of Kayser-Fleischer rings level 2 tests are important for diagnostic confirmation of WD. Liver biopsy for hepatic copper concentrations is an invaluable diagnostic tool. Most homozygotes for WD have levels > 250 µg/g dry weight with normal values rarely exceeding 50 µg/g. Intermediate values may be seen in heterozygotes. A number of hepatic conditions manifesting extreme cholestasis may have elevated hepatic copper concentrations but can usually be diagnosed by other clinical, serologic, or histologic criteria. Liver biopsies may be evaluated for copper concentration after being dried overnight at 56°C in a vacuum oven with part of the biopsy specimen separated and fixed in formalin prior to histopathologic evaluation. The evaluation should include immunohistochemical staining for copper.

Level 3 tests include incorporation of radiocopper into ceruloplasmin and molecular genetic studies to provide evidence for mutations in the ATP7B gene. In practice, the incorporation of isotopes of copper into ceruloplasmin is impractical in most centers. Such tests have been used to validate the diagnosis of WD in the minority of patients with normal ceruloplasmin levels, or where there was previously a contraindication to liver biopsy. The availability of the transjugular route of liver biopsy has made such tests unnecessary in most circumstances.

Currently, molecular genetic studies are confined to haplotype analysis of family members of an affected individual. Such tests involve evaluation of DNA polymorphisms in the nucleotide regions surrounding the ATP7B gene. There have been multiple disease-specific mutations of the WD gene described in probands with the disorder. Even the most common of these mutations account for only 15% to 30% of most WD populations. Newer technologies that utilize molecular genetic testing in newly discovered patients with clinical manifestations of the disease might pinpoint disease-specific mutations in contradistinction to polymorphisms of the gene. TREATMENT Depending on the mode of presentation of WD, treatment options consist of either orally administered pharmacologic agents (Table 4) or OLT. Liver transplantation should not be regarded as a treatment of last resort, but it may be the only means of timely intervention in patients presenting with acute or subacute liver failure or decompensating end-stage liver disease. Ideally, patients should be diagnosed early enough for medical therapy to attenuate or abolish symptoms and prevent progression of the disease. It is generally agreed that patients with symptoms or signs of hepatic insufficiency or chronic active hepatitis with or without neurologic manifestations should be offered chelation therapy with penicillamine or trientine. These drugs are administered orally and remove copper from potentially toxic sites. In contrast, zinc salts serve to block the intestinal absorption of dietary copper by stimulating the synthesis of a variety of endogenous copper chelators such as metallothioneins. Penicillamine was the first copper chelator to be developed and unfortunately has been incriminated in a variety of toxic side effects that lead to discontinuation of the drug in 10% to 15% of patients1,8,9 Trientine was developed more recently and is considered preferable by many experts as first-line therapy in patients with hepatic and/or neurologic disease. Zinc salts may be considered as initial therapy for asymptomatic patients or for those intolerant of penicillamine or trientine.8 With any of these treatments, patients should be evaluated for clinical and biochemical improvement and normalization of markers of copper metabolism, in particular the level of free serum copper and urinary copper output. With stabilization of these clinical and biochemical parameters, patients may be switched to maintenance therapy. This may consist of reduction in the dose of penicillamine or trientine or, in some cases, switching from these chelating agents to zinc salts (Table 4).

Dietary intake of foods rich in copper should be avoided, particularly during the initial phase of treatment. Organ meats, nuts, chocolate, and shellfish should be avoided. These restrictions may be partially lifted during the maintenance phase of treatment.

For WD patients who become pregnant, the doses of penicillamine or trientine should be reduced during the second trimester and the first 2 months of the third trimester to 500 mg/day maximum, and to 250 mg/day for the month before delivery and for up to 1 month postpartum.8,10 A similar approach to reduction in therapy with chelating agents is applied to patients undergoing surgery, to allow wound healing to be completed.

The key to long-term success of pharmacologic treatment for WD is the patient's adherence to treatment. Evaluation of response is based upon improvement in the signs of liver or neurologic disease and improvement in biochemical markers of liver function. Further assessment is based on periodic monitoring of urinary copper output, slit-lamp examinations and, most important, by reduction in the level of non-ceruloplasmin-bound copper in the serum. With adequacy of treatment, this should fall to 10 µg/dL or less. Inadequate treatment or failure of compliance is usually associated with a level above 25 µg/dL. In the context of chelation therapy, urinary copper excretion initially exceeds 1,000 µg/day, and subsequently on maintenance treatment should be between 250 and 500 µg/day. Values less than this usually suggest nonadherence to treatment. In contrast, on zinc therapy, urinary copper excretion usually falls to < 150 µg/day.

OLT is indicated in the extreme circumstances mentioned above, when there is evidence of impending liver failure.11 Transplant recipients develop the normal donor phenotype with regard to markers of copper metabolism and do not require additional pharmacologic therapy for WD, except possibly in the circumstances of residual neurologic symptoms and signs. OUTCOMES Even with established cirrhosis or chronic active hepatitis, the prognosis is excellent for patients who adhere fully to pharmacologic therapy. Neurologic or psychiatric symptoms may be slow to recover and may not be completely reversible. However, features of both neurologic disease and hepatic insufficiency usually stabilize on treatment, and only a watch-and-wait approach can be recommended. In cases of liver decompensation, following OLT 1-year survival is comparable to that for other causes of liver failure.11 Although neurologic symptoms may improve post-OLT, the extent of neurologic involvement itself in the absence of liver failure is not an indication for OLT.

 

資料來源:[http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/gastro/wilsons/wilsons.htm]